Investigational Drug Versus an Approved Drug in Patients With Rheumatoid Arthritis (0663-072)

Organon

Status and phase: Completed; Phase 3

Conditions: Rheumatoid Arthritis

Treatments: Drug: Comparator: Diclofenac sodium; Drug: MK0663, etoricoxib

Study type: Interventional

Funder types: Industry

Identifiers

NCT00092742

0663-072

2004_055

Details and patient eligibility

About

The purpose of this study is to evaluate the long-term safety of an investigational drug versus an approved drug for the relief of pain in patients with rheumatoid arthritis.

Full description

The duration of treatment is 12 months.

Enrollment: 4,086 patients

Sex: All

Ages: 50+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Males and females 50 years or older with rheumatoid arthritis.

Exclusion criteria

• History of gastrointestinal malabsorption or inflammatory bowel disease
• History of heart problems such as: congestive heart failure (CHF), heart attack or high blood pressure.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind